Skip to main content
Equibles

Jason Haas

Analyst

Wells Fargo

Analyst

Bank of America

Board Member

Ligand Pharmaceuticals Inc (LGND)

Equibles does not estimate personal net worth.

About Jason Haas

Jason Haas is recorded as Analyst at Wells Fargo, Analyst at Bank of America and Board Member at Ligand Pharmaceuticals Inc (LGND). The newest filing on record that lists Jason Haas as Board Member at Ligand Pharmaceuticals Inc (LGND) is dated April 21, 2026. Ligand Pharmaceuticals Inc reported in an 8-K filed June 9, 2026 that Jason Haas was appointed director of the Company, effective June 5, 2026. Ligand Pharmaceuticals Inc reported in an 8-K filed June 17, 2024 that Jason Haas was appointed director. Jason Haas has spoken on 43 earnings calls and 4 other investor events across 17 companies, most recently for Moodys Corp on October 21, 2026. Those appearances were for S&P Global Inc. (SPGI), Ecolab Inc. (ECL), Verisk Analytics, Inc. (VRSK), Factset Research Systems Inc (FDS), Equifax Inc (EFX) and 12 other companies. Ligand Pharmaceuticals Inc is classified in the Biotechnology industry within the Healthcare sector. Other companies whose calls Jason Haas spoke on are classified in the Financial Services, Basic Materials, Industrials and Consumer Cyclical sectors. Other leadership on record at Ligand Pharmaceuticals Inc includes Todd C. Davis (CEO and Board Member), Tavo Espinoza (CFO), Jason M. Aryeh (Board Member) and 7 others.

“Jason Haas | 17,204,420 | 329,339 | 1,257,231”
Ligand Pharmaceuticals Inc Form 8-K, filed June 9, 2026 · Read the filing
“each nominee was elected to serve as a director of the Company.”
Ligand Pharmaceuticals Inc Form 8-K, filed June 17, 2024 · Read the filing

Jason Haas on recent calls

“I wanted to ask about some recent high-profile fines for some KYC and anti-money-wandering lapses at some large financial institutions that made some pretty big headlines.”
Analyst — Wells Fargo, 3Q 2026 Earnings Conference Call ·
“And I'm curious to hear your thoughts on what you think the staying power of MCP is. We've heard that some of the newer AI models don't necessarily need to use MCP.”
Analyst — Wells Fargo, FactSet Fourth Quarter 2026 Webcast ·
“Can I just confirm in a follow-up and a response to a prior question? Did you see that you would expect the EWS business to get back to the long-term framework next year?”
Analyst — Wells Fargo, Q3 2026 ·
“I wanted to follow up on an earlier response to a question around incremental margins. I thought you said that the guidance implies incremental margins this year of 32% to 34%.”
Analyst — Wells Fargo, Cintas Corp Q1 FY2027 Earnings Call ·
“I'm curious if you could give us a sense for what percentage of your data is now available for MTP consumption, and what does the pricing model look for that? Are you charging customers more for access to the data via an MTP?”
Analyst — Wells Fargo, NIQ Second Quarter Earnings Webcast ·

Affiliation history

  • Wells Fargo

    Analyst

    Source not stated

    Current

  • Bank of America

    Analyst

    Source not stated

    Current
  • Ligand Pharmaceuticals Inc (LGND)

    Board Member

    Proxy statement

    Current

    Start not stated–present

    Last confirmed April 21, 2026

Company network

Leadership on record at Ligand Pharmaceuticals Inc

Recent activity

Show 37 earlier activities